Exploratory Study Evaluating the Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris, Using a Split-Face Model

The aim of this proof of principle study is to evaluate efficacy and safety of the sequential application of two marketed products for the treatment of acne vulgaris, using the Split-Face model

Start Date01 Nov 2011

Sponsor / Collaborator

Leo Pharma, Inc.

100 Clinical Results associated with Tretinoin Tocoferil

100 Translational Medicine associated with Tretinoin Tocoferil

100 Patents (Medical) associated with Tretinoin Tocoferil

Literatures (Medical) associated with Tretinoin Tocoferil

01 May 2020·Lung CancerQ2 · MEDICINE

Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC)

Q2 · MEDICINE

Article

Author: Dudnik, Elizabeth ; Rotem, Ofer ; Moore, Assaf ; Shochat, Tzippy ; Sherman, Shira ; Zer, Alona

OBJECTIVESLittle is known regarding the ICPi efficacy in LCNEC. We explored the efficacy and safety of ICPi in LCNEC and assessed its impact on OS.MATERIALS AND METHODSThirty-seven consecutive patients with advanced LCNEC were selected from the Davidoff Cancer Center database. These were divided into groups A1 (patients treated with ICPi, n-23) and A2 (patients not treated with ICPi, n-14). Additionally, group A1* was introduced (patients treated with ICPi as a monotherapy, n-21). Another cohort of advanced non-LCNEC lung cancer patients treated with nivolumab at five Israeli cancer centers was chosen as a comparator (group B, n-270). ORR, PFS with ICPi in group A1* were assessed (RECIST 1.1), OS with ICPi was compared between groups A1* and B. OS since advanced disease diagnosis (OSDx) was compared between groups A1 and A2.RESULTSIn group A1*, ORR and median PFS with ICPi were 33 %, and 4.2 months (95 % CI, 2.4-8.1), respectively. With median follow-up since start of ICPi of 6.2 months [IQR 2.2-12.1] and 4.9 months [IQR 2.3-8.9] in groups A1* and B, respectively, 52 % and 64 % of patients died in groups A1* and B, respectively. Median OS with ICPi comprised 11.8 months (95 % CI, 3.7-NR) and 6.9 months (95 % CI, 5.5-8.1) in groups A1* and B, respectively (p-0.23). Median OSDx was 14.5 months (95 % CI, 10.1-38.9) and 10.3 months (95 % CI, 2.6-NR), in groups A1 and A2, respectively (p-0.54).CONCLUSIONIn advanced LCNEC, ICPi outcomes are comparable to the outcomes observed in advanced NSCLC. Future research is needed to clarify the impact of ICPi on OS, and to correlate its benefit with tumor mutational landscape.

01 Oct 2013·Journal of Dermatological ScienceQ2 · MEDICINE

Reagents inducing epidermal proliferation also induce pigmentation: Induction of keratinocyte proliferation as a novel strategy for the treatment of vitiligo

Q2 · MEDICINE

Letter

Author: Mayumi Komine ; Mamitaro Ohtsuki ; Chieh-Shan Wu ; Yayoi Tada ; Kanako Kikuchi ; Seiki Fujimoto ; Hanako Ohmatsu ; Hsin-Su Yu ; Kunihiko Tamaki

A review.This article hypothesis the reagents inducing epidermal keratinocytes proliferation also induce pigmentation for treatment of vitiligo.The reagents used for proliferation are tacrolimus, alprostadil, alfadex, bendazac, etretinate, trafermin, phenytoin, bucladesine sodium, tretinoin tocoferil.

01 Oct 2012·Pharmaceutical ResearchQ3 · MEDICINE

Powder Strength Distributions for Understanding De-agglomeration of Lactose Powders

Q3 · MEDICINE

Article

Author: Srinivas Ravindra Babu Behara ; David Alexander Vodden Morton ; Ian Clair Larson ; Jurgen Bernd Bulitta ; Peter James Stewart ; Shyamal Chandra Das

PURPOSEThe purpose was to calculate distributions of powder strength of a cohesive bed to explain the de-agglomeration of lactose.METHODSDe-agglomeration profiles of Lactohale 300(®) (L300) and micronized lactose (ML) were constructed by particle sizing aerosolised plumes dispersed at air flow rates of 30-180 l/min. The work of cohesion distribution was determined by inverse gas chromatography. The primary particle size and tapped density distributions were determined. Powder strength distributions were calculated by Monte Carlo simulations from distributions of particle size, work of cohesion and tapped density measurements.RESULTSThe powder strength distribution of L300 was broader than that of ML. Up to 85th percentile, powder strength of L300 was lower than ML which was consistent with the better de-agglomeration of L300 at low flow rates. However, ~15% of L300 particles had higher powder strength than ML which likely to cause lower de-agglomeration for L300 at high air flow rates.CONCLUSIONCohesive lactose powders formed matrices of non-homogenous powder strength. De-agglomeration of cohesive powders has been shown to be related to powder strength. This study provided new insights into powder de-agglomeration by a new approach for calculating powder strength distributions to better understand complex de-agglomeration behaviour.

100 Deals associated with Tretinoin Tocoferil

External Link

KEGG	Wiki	ATC	Drug Bank
D01516	-	D10AD01 L01XX14	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pressure Ulcer	JP	Sun Pharmaceutical Industries Ltd.	02 Oct 1992

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01461655 (CTgov)	Phase 2	Acne Vulgaris	40	vehicle gel+marketed topical retinoid (Topical Retinoid - Placebo)	wpdrrocpgp(xhykswpxgn) = dbdauqciuf mxwvmeeyjz (phqnbkgtwa, ihvngbxuvq - ezxvuvzufx) View more	-	04 Dec 2013
				marketed topical NSAID+marketed topical retinoid (Topical Retinoid-NSAID)	wpdrrocpgp(xhykswpxgn) = vlzdeuizvq mxwvmeeyjz (phqnbkgtwa, vhkphddltq - wxrnggbojw) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Tretinoin Tocoferil

Overview

Basic Info

Structure

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation